mRNA-based telomere extension therapy using proprietary lipid nanoparticle delivery to reverse cellular aging in specific tissues.
Rejuvenation Technologies is developing a clinical-stage therapeutic platform using modified mRNA delivered via proprietary lipid nanoparticles to temporarily activate telomerase and extend telomeres in targeted human cells. The company holds over 40 granted patents and has received more than $8M in grant funding since 2023. Target disease areas include pulmonary fibrosis, liver disease, and bone marrow failure. Preclinical studies have demonstrated reversal of 5+ years of telomere shortening in one day. Rejuvenation Technologies is a product of Rejuvenation Technologies Inc..